- Sections
- C - Chimiemétallurgie
- C07D - Composés hétérocycliques
- C07D 207/24 - Atomes d'oxygène ou de soufre
Détention brevets de la classe C07D 207/24
Brevets de cette classe: 96
Historique des publications depuis 10 ans
|
4
|
2
|
6
|
12
|
5
|
3
|
8
|
6
|
6
|
3
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Propriétaires principaux
| Proprétaire |
Total
|
Cette classe
|
|---|---|---|
| Novartis AG | 10656 |
4 |
| Merck Patent GmbH | 5756 |
3 |
| BioCryst Pharmaceuticals, Inc. | 169 |
3 |
| Omeros Corporation | 308 |
3 |
| The United States of America, as represented by the Secretary, Department of Health and Human Services | 2895 |
3 |
| Vettore, LLC | 16 |
3 |
| Bristol-myers Squibb Company | 4848 |
2 |
| 3m Innovative Properties Company | 17752 |
2 |
| Janssen Pharmaceutica N.V. | 3349 |
2 |
| Pfizer Inc. | 3397 |
2 |
| Allergan, Inc. | 2315 |
2 |
| Northwestern University | 3442 |
2 |
| Eli Lilly and Company | 3898 |
2 |
| MedImmune Limited | 625 |
2 |
| National Institute of Biological Sciences, Beijing | 100 |
2 |
| NDSU Research Foundation | 243 |
2 |
| Shanghai Puyi Chemical Technology Co. Ltd | 2 |
2 |
| Vironova Thionation AB | 5 |
2 |
| Evonik Operations GmbH | 4160 |
2 |
| Petra Pharma Corporation | 35 |
2 |
| Autres propriétaires | 49 |